INMB

+ Watchlist + Portfolio

INmune Bio Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.23
52-Week Range: $1.09 – $2.44
Market Cap: $59.95M
P/E (TTM): —
EPS (TTM): -0.62
Dividend Yield: —

Advanced Metrics

Price/Book: 2.93
PEG Ratio: —
Return on Equity: -74.82%
Return on Assets: -39.12%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.04
Debt/Equity: 0.07
Total Debt: $1.41M
Free Cash Flow: $-10.05M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $44.88M

INMB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$374.00K	$155.00K	$14.00K	$50.00K
Research & Development	$17.07M	$20.27M	$33.17M	$20.66M
Selling, General & Admin	$9.26M	$9.62M	$9.48M	$10.26M
Operating Expenses	$26.32M	$29.90M	$42.65M	$30.92M
Operating Income	-$25.95M	-$29.74M	-$42.63M	-$30.87M
EBITDA	-$25.95M	-$29.74M	-$42.63M	-$30.79M
Pretax Income	-$27.30M	-$30.01M	-$42.08M	-$45.93M
Net Income	-$27.30M	-$30.01M	-$42.08M	-$45.93M
Diluted EPS	-1.52	-1.67	-2.11	-1.86
Diluted Shares	17.93M	17.98M	19.94M	24.76M

INMB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$52.15M	$35.85M	$20.92M	$24.75M
Receivables	$8.46M	$2.44M	$1.41M	$4.54M
Current Assets	$64.67M	$39.94M	$22.66M	$29.89M
Total Assets	$81.80M	$57.00M	$39.56M	$32.35M
Current Liabilities	$10.92M	$18.46M	$7.22M	$8.42M
Long-Term Debt	$9.70M	—	—	—
Total Debt	$15.31M	$10.44M	$384.00K	$1.03M
Total Liabilities	$21.69M	$18.86M	$7.46M	$8.83M
Retained Earnings	-$91.01M	-$121.02M	-$163.10M	-$209.04M
Shareholders' Equity	$60.10M	$38.14M	$32.10M	$23.52M
Working Capital	$53.76M	$21.48M	$15.44M	$21.47M

INMB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$22.69M	-$11.98M	-$33.36M	-$22.58M
Capital Expenditure	—	—	—	-$1.04M
Free Cash Flow	-$22.69M	-$11.98M	-$33.36M	-$23.62M
Depreciation & Amortisation	—	—	$0.00	$84.00K
Stock-Based Compensation	$7.15M	$7.37M	$7.61M	$9.91M
Investing Cash Flow	$0.00	—	$0.00	-$1.04M
Financing Cash Flow	$729.00K	-$4.22M	$18.21M	$27.61M
Net Change in Cash	-$21.96M	-$16.20M	-$15.15M	$3.99M

INMB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$50.00K	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.64M	$5.80M	$4.89M	$2.33M	$3.64M
Selling, General & Admin	$2.32M	$2.25M	$2.55M	$3.15M	$2.17M
Operating Expenses	$9.96M	$8.06M	$7.43M	$5.47M	$5.81M
Operating Income	-$9.90M	-$8.06M	-$7.43M	-$5.47M	-$5.81M
EBITDA	-$9.90M	-$8.06M	-$7.43M	-$5.42M	-$5.76M
Pretax Income	-$9.74M	-$24.46M	-$6.47M	-$5.26M	-$5.41M
Net Income	-$9.74M	-$24.46M	-$6.47M	-$5.26M	-$5.41M
Diluted EPS	-0.43	-1.05	-0.24	—	-0.20
Diluted Shares	22.50M	23.30M	26.59M	—	26.59M

INMB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$19.34M	$33.37M	$27.73M	$24.75M	$21.36M
Receivables	$1.42M	$2.15M	$2.46M	$4.54M	$770.00K
Current Assets	$20.96M	$36.03M	$30.67M	$29.89M	$22.82M
Total Assets	$37.80M	$37.68M	$33.36M	$32.35M	$25.82M
Current Liabilities	$7.93M	$8.59M	$7.36M	$8.42M	$5.39M
Total Debt	$347.00K	$451.00K	$1.08M	$1.03M	$1.51M
Total Liabilities	$8.13M	$8.82M	$7.98M	$8.83M	$6.19M
Retained Earnings	-$172.84M	-$197.30M	-$203.77M	-$209.04M	-$214.44M
Shareholders' Equity	$29.67M	$28.87M	$25.38M	$23.52M	$19.62M
Working Capital	$13.03M	$27.45M	$23.31M	$21.47M	$17.43M

INMB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.82M	-$7.38M	-$5.44M	-$2.94M	-$3.40M
Capital Expenditure	—	—	-$193.00K	-$143.00K	—
Free Cash Flow	-$6.82M	-$8.08M	-$5.63M	-$3.09M	-$3.40M
Depreciation & Amortisation	$0.00	—	—	$56.00K	$52.00K
Stock-Based Compensation	$2.08M	$1.53M	$2.98M	$3.32M	$1.50M
Investing Cash Flow	—	—	-$193.00K	-$143.00K	—
Financing Cash Flow	$5.27M	$22.27M	$0.00	$67.00K	$0.00
Net Change in Cash	-$1.55M	$14.19M	-$5.63M	-$3.02M	-$3.40M

Market Snapshot

About

INmune Bio Inc. is a clinical-stage immunology company developing treatments for cancer and neurodegenerative diseases. The company's approach focuses on reprogramming the patient's innate immune system to treat disease. INmune Bio's pipeline includes therapies targeting treatment-resistant cancers and Alzheimer's disease, with lead programs in clinical trials. The company's proprietary technology platform aims to enhance the immune system's ability to recognize and destroy diseased cells while preserving healthy tissue.